IL13Ralpha2 hinge-optimized 41BB CAR truncated CD19-expressing autologous T-cells (City of Hope)

This autologous chimeric antigen receptor (CAR) T-cell therapy targets the interleukin-13 receptor alpha 2 (IL13Rα2), a tumor-associated antigen frequently overexpressed in glioblastoma and other high-grade gliomas. The construct utilizes a hinge-optimized IL-13 ligand containing an E13Y mutation (often referred to as the EQ mutation) to enhance binding specificity for IL13Rα2 while reducing affinity for the more widely expressed IL13Rα1. The CAR architecture includes a 4-1BB (CD137) costimulatory domain and a CD3ζ signaling domain to promote T-cell persistence and anti-tumor activity. Additionally, the cells are engineered to express a truncated human CD19 (CD19t) as a non-immunogenic surface marker, which facilitates the tracking of CAR T-cells in vivo and provides a potential mechanism for cell ablation if necessary. Developed by City of Hope and licensed to Mustang Bio, this therapy is primarily administered via intratumoral or intraventricular routes to bypass the blood-brain barrier.

Other names

IL13Ralpha2-targeted CAR T cellsIL-13Ralpha2-targeted CAR T cellsIL 13Ralpha2-targeted CAR T cellsIL13Rα2-specific CAR T cellsIL13Ralpha2-CAR T cellsIL-13Ralpha2-CAR T cellsIL 13Ralpha2-CAR T cells